Roche Breast Cancer Drug Receives FDA Approval

By Admin
The US Food and Drug Administration announced on Friday that it had approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose canc...

 

The US Food and Drug Administration announced on Friday that it had approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose cancer cells contain increased amounts of a protein known as HER2.

The drug's label will carry a boxed warning, the most serious possible, of the drug's potential to cause liver and heart damage and death. The drug can also cause life-threatening birth defects.

In clinical trials, patients who took the drug, known during its development process as T-DM1, survived an average of 30.9 months, compared with 25.1 months in a control group.

Analysts at Jefferies have estimated the drug could generate annual peak sales of $1.9 billion as usage in different settings increases.

Kadcyla works by attaching trastuzumab, sold under the brand name Herceptin, to a drug called DM1 that interferes with cancer cell growth, said Dr Richard Pazdur, Director of the FDA's Office of Hematology and Oncology Products.

“Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolong survival,” he said. “It is the fourth approved drug that targets the HER2 protein.”

Breast cancer is the second leading cause of cancer-related death among women. An estimated 232,340 women will be diagnosed with the disease in 2013 and 39,620 will die from it, according to the National Cancer Institute. About 20 percent of breast cancer patients have increased amounts of the HER2 protein.

The most common side effects in patients treated with Kadcyla were nausea, fatigue, muscle and joint pain, increased liver enzymes, headache and constipation.

Source: Reuters

Share

Featured Articles

Mental health support for working women and mothers

Dr. Kylie Bennett, Mental Health Program Director at Dialogue, is committed to supporting women in the workplace - especially Mothers - and their health

Digital evolution delivers better healthcare outcomes

Hannah Graham, Group Account Director at digital transformation consultancy Equator, shares how digitisation is building positive changes in healthcare

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Technology & AI

Healthcare Digital news roundup: prostate cancer & AI

Medical Devices & Pharma

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare